Press Releases

The U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). Today's approval represents the first drug approved for the treatment of thyroid eye disease.   "Today's approval marks an important milestone for the treatment of thyroid eye dis

Cambridge Healthtech Institute (CHI) today announced the return of Bioprocessing Summit Europe --the fastest growing bioprocessing meeting on the continent—with the addition of approximately 30 new sessions on Analytical and Formulation topics. Now in its third year, the March 24-26, 2020 conference is moving to The Crowne Plaza Barcelona–Fira Center, Barcelona, Spain, to accommodate increased registrations, which have doubled since the meeting was launched in 2018.

As the pharmaceutical market demands in China continue to grow, China’s pharmaceutical policies become gradually clear, which provides broad space for the development of pharmaceutical enterprises. The CRO & CMO industry, an important part of the R&D industry chain of pharmaceutical enterprises, has also ushered in important development opportunities. The Asia-Pacific region, a representative of the emerging CRO & CMO markets, is now in the golden period of development, lead

FDF China,collocated with CPhI China, will be held fromJune 22-24, 2020 at Shanghai New International Expo Centre (SNIEC). More and more formulation enterprises need to implement strategic layout to step up cooperation in innovation and facilitate the integration of science and technology with economic growth and increase the sharing of innovation results.   New pharmaceutical industry structure, new high ground through innovation The newly revised dr

As a world-renowned vertical trade and exchange event of the pharmaceutical industry, CPhI & P-MEC China 2020will take place at Shanghai New International Expo Centre (SNIEC) June 22-24, 2020. The exhibition will reach a scale of 210,000m2,facilitate over 3,400 Chinese and overseas exhibitors to showcase innovative products and advanced technologies, and jointly unlock a grand gala of the pharmaceutical industry with over 75,000 professional visits from more than 140 countries and regions

To seize the ever-changing opportunities in the new era and to meet the ever-growing market demands, the annual gala of the biopharmaceutical industry--- bioLIVE China 2020, will be held again at Hall W4 in the SNIEC on June 22-24, 2020. The exhibition, co-located with CPhI China 2020, will build an international trade platform of information sharing and business cooperation for professionals from sectors of biopharmaceuticals, biotechnology, new drug R&D, and pharmaceutical investment, e

Global procurement management of pharmaceutical packaging materials has become a hot issue that all pharmaceutical enterprises are facing under the economic globalization. Rational packaging procurement will not only help to achieve the balance between functionality and cost but also prevent shortsupply. Therefore, how to efficiently obtain accurate information on potential suppliers appears to be particularly important.

AT & IT China 2020, organized by Informa Markets and China Chamber of Commerce for Import & Export of Medicines & Health Products and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd., totake place at the Shanghai New International Expo Centre on June 22-24, 2020 together with CPhI & P-MEC China 2020, will focus on automatic production, information system layout, network security, and the new trend of safety and lean manufacturing of the phar

P-MEC China, co-organized by Informa Markets, CCCMHPIE and Sinoexpo Informa Markets,will take place at the Shanghai New International Expo Center (SNIEC) on 22-24 June 2020. The event will be co-located with CPhI China with total area exceeding 210,000m2 and over 75,000 visits of professionals are expected. P-MEC China unveiled as a co-locate of CPhI China with the rising

Polaryx Therapeutics, a biotech company developing patient-friendly small molecule therapeutics for lysosomal storage disorders announced today that the Company has received an Investigational New Drug Application (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of LINCL patients with PLX-200. Neuronal Ceroid Lipofuscinoses are a group of rare autosomal recessive neurodegenerative lysosomal storage disorders. Among them, LINCL is caused by mutations